Trial Profile
A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb5871 on Systemic Lupus Erythematosus Disease Activity
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Obexelimab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Xencor
- 17 Jul 2023 Primary endpoint has not been met, (proportion of patients reaching Week 32 without LOI), as per Results published in the Arthritis and Rheumatology
- 17 Jul 2023 Results published in the Arthritis and Rheumatology
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism